NDA 212501 · Dr Reddys
Cyclophosphamide
Cyclophosphamide · Intravenous · Alkylating Drug
Last checked: Nov 19, 2026Latest source record: Mar 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jul 30, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5,442
943 Phase 3, 897 recruiting
FAERS reports
179,391
172,655 serious, 36,268 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 7, 2025.
Cyclophosphamide is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1.1 ) 1.1 Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- CYCLOPHOSPHAMIDE · CYCLOPHOSPHAMIDE 2GM/10ML (200MG/ML) · SOLUTION, INTRAVENOUS · Prescription
- CYCLOPHOSPHAMIDE · CYCLOPHOSPHAMIDE 500MG/2.5ML (200MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- CYCLOPHOSPHAMIDE · CYCLOPHOSPHAMIDE 1GM/5ML (200MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Cyclophosphamide" as an intervention, any sponsor and status, largest first.
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00103285 · 5,377 participants · Start Apr 11, 2005 · Primary completion Dec 30, 2013
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 236 sites in all
- Combination Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA (cT1-3, N0-1, M0) Breast Cancer and Positive Axillary Lymph NodesPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00003782 · 5,351 participants · Start Mar 1999 · Primary completion Dec 2008
Drug: cyclophosphamide; docetaxel and 1 more · For: Breast Cancer
Sites: Huntsville, Alabama; Anchorage, Alaska; Phoenix, Arizona · 157 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use16,826
- febrile neutropenia14,787
- drug ineffective10,788
- neutropenia10,780
- pyrexia9,368
- disease progression8,229
- pneumonia6,779
- thrombocytopenia6,679
- product use in unapproved indication6,563
- nausea6,354
- anaemia6,286
- sepsis5,803
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1,541 |
| 2005 | 1,760 |
| 2006 | 1,662 |
| 2007 | 1,990 |
| 2008 | 2,643 |
| 2009 | 3,104 |
| 2010 | 3,472 |
| 2011 | 5,665 |
| 2012 | 5,198 |
| 2013 | 3,764 |
| 2014 | 4,002 |
| 2015 | 5,802 |
| 2016 | 5,819 |
| 2017 | 7,870 |
| 2018 | 11,680 |
| 2019 | 12,218 |
| 2020 | 12,590 |
| 2021 | 12,754 |
| 2022 | 15,807 |
| 2023 | 17,132 |
| 2024 | 17,177 |
| 2025 | 15,538 |
| 2026 | 10,200 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cyclophosphamide* (Cyclophosphamide)
2024 spending
$2.1M
Beneficiaries
1,739
5,947 claims
Per beneficiary
$1,189
$74.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,340,840 |
| 2021 | $2,857,636 |
| 2022 | $2,941,150 |
| 2023 | $2,681,596 |
| 2024 | $2,067,490 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH, Merkel PA, Spiera R, et al. · N Engl J Med 2010 · Multicenter Study, Randomized Controlled Trial
- Infliximab versus Cyclophosphamide for Severe Behçet's Syndrome.
Saadoun D, Maalouf G, Vieira M, et al. · NEJM Evid 2024 · Clinical Trial, Phase II, Comparative Study
- Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
de Groot K, Harper L, Jayne DR, et al. · Ann Intern Med 2009 · Multicenter Study, Randomized Controlled Trial
- Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.
Maher TM, Tudor VA, Saunders P, et al. · Lancet Respir Med 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.
Austin HA, Klippel JH, Balow JE, et al. · N Engl J Med 1986 · Clinical Trial, Comparative Study
- Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
Harper L, Morgan MD, Walsh M, et al. · Ann Rheum Dis 2012 · Comparative Study, Randomized Controlled Trial
Sponsor: Dr Reddys
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.